Subtype
Endocrine Carcinoma
CI-CAN-00000838Explore in graph →
574 active trials16 approved drugs58 evidence items
- NCIt
- C215715
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000838Explore in graph →
Clinical trials
1,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (236)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04640480 | Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors | completed | Phase 1 | 21 | SN BioScienceINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT03575793 | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 39 | Salma SabbourOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05001971 | Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy | completed | Phase 2 | 65 | Hunan Cancer HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT02324647 | Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield(SERENDIPITY) | completed | — | 807 | University Medical Center GroningenOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07316309 | CXCR4 PET/CT for Predicting Outcome in Limited-Stage Small Cell Lung Cancer | completed | — | 33 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT00213798 | Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients | completed | N/A | 200 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT03290079 | Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors | completed | Phase 2 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04063163 | A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC | completed | Phase 3 | 585 | Shanghai Henlius BiotechINDUSTRY | 5 | Dec 9, 2025 | clinicaltrials |
| NCT05339022 | Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial | completed | N/A | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05329623 | A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04631029 | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2025 | clinicaltrials |
| NCT04885998 | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) | completed | Phase 1 | 23 | AmgenINDUSTRY | 6 | Sep 29, 2025 | clinicaltrials |
| NCT02514447 | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | completed | Phase 1 / Phase 2 | 123 | G1 Therapeutics, Inc.INDUSTRY | 8 | Sep 25, 2025 | clinicaltrials |
| NCT03041311 | Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC | completed | Phase 2 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 25, 2025 | clinicaltrials |
| NCT04221529 | Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide(SPACE) | completed | Phase 2 | 70 | AIO-Studien-gGmbHOTHER | 2 | Sep 8, 2025 | clinicaltrials |
| NCT04462471 | Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers | completed | Phase 1 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT01737502 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 29 | Mayo ClinicOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT02820857 | Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer(BEVANEC) | completed | Phase 2 | 153 | Hospices Civils de LyonOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06439745 | More Than 50% of Unifocal cN0 T1b/Small T2 Papillary Thyroid Carcinoma May Require Completion Thyroidectomy if Nodal Status is Evaluated(cN0PTC) | completed | — | 314 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Sep 2, 2025 | clinicaltrials |
| NCT02973997 | Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) | completed | Phase 2 | 57 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05509699 | Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 21 | Hutchison Medipharma LimitedINDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT01723202 | Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer | completed | Phase 2 | 53 | Bhavana KondaOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT05752669 | Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.(TEMPEST) | completed | — | 100 | Istituto Auxologico ItalianoOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT07132957 | A Study of AL8326 in Healthy Subjects | completed | Phase 1 | 6 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT01879657 | 68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs) | completed | N/A | 169 | Radio Isotope Therapy of AmericaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07107503 | 10 Years' Follow-up Results of Ultrasound-guided Radiofrequency Ablation Versus Surgery for Low-risk Papillary Thyroid Micro-carcinoma | completed | — | 757 | Yi MaoOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT03599713 | A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) | completed | Phase 2 | 107 | Incyte CorporationINDUSTRY | 12 | Aug 5, 2025 | clinicaltrials |
| NCT04197960 | Microwave Ablation and Surgical Resection for Micropapillary Thyroid Carcinoma | completed | N/A | 973 | Chinese PLA General HospitalOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT02769832 | Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer | completed | Phase 2 | 32 | Muhammad FurqanOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07066644 | Intraoperative Pathologic Evaluation of Central Lymph Nodes in Papillary Thyroid Carcinoma | completed | — | 509 | Seoul National University HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT03382561 | Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 160 | National Cancer Institute (NCI)NIH | 1 | Jul 3, 2025 | clinicaltrials |
| NCT04400188 | A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 25 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05534594 | Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer(MIMETIC) | completed | N/A | 8 | University Medical Center GroningenOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06826677 | REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER(ARAL) | completed | — | 71 | AstraZenecaINDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT02324296 | PEI REGIMEN: A Therapeutic Option in Small Cell Lung Cancer? A Monoinstitutional Experience of 46 Consecutive Cases | completed | — | 46 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 0 | Jun 11, 2025 | clinicaltrials |
| NCT04358237 | Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.(LUPER) | completed | Phase 1 / Phase 2 | 28 | Antonio Calles BlancoOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
| NCT03783078 | Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) | completed | Phase 3 | 55 | Merck Sharp & Dohme LLCINDUSTRY | 8 | May 28, 2025 | clinicaltrials |
| NCT04314895 | Trial of NanoPac Intratumoral Injection in Lung Cancer | completed | Phase 2 | 18 | NanOlogy, LLCINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT04774380 | Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer(LUMINANCE) | completed | Phase 3 | 152 | AstraZenecaINDUSTRY | 6 | May 23, 2025 | clinicaltrials |
| NCT04129411 | Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation | completed | N/A | 5 | Mayo ClinicOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT03554473 | M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers | completed | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | May 9, 2025 | clinicaltrials |
| NCT02230176 | Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II(OCCLURANDOM) | completed | Phase 2 | 84 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT02487095 | Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers | completed | Phase 1 / Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2025 | clinicaltrials |
| NCT02196961 | Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation(ADMEC-O) | completed | Phase 2 | 180 | Prof. Dr. med. Dirk SchadendorfOTHER | 2 | Apr 9, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jan 27, 2026source: clinicaltrials